

Singlera Genomics raises funds worth \$60M

28 March 2018 | News

The funds will help Singlera expand the development and commercialization of its non-invasive genetic tests for early-stage cancer detection and clinical validation studies.



Singlera Genomics, a non-invasive genetic diagnostics company that focuses on early-stage cancer detection, has successfully secured a \$60 million Series A+ financing round led by Green Pine Capital Partners and Prosperico Ventures with participation from new and existing investors, UCF Medical Investment, Jointown Pharmaceutical Group, and Lilly Asia Ventures among others.

Based in La Jolla and Shanghai, Singlera has developed proprietary technologies related to the analysis of cell-free DNA. Singlera's main products and services include cancer screening, diagnosis and personalized treatment.

Singlera is striving to improve clinical outcomes for cancer patients through early-stage detection and accurate and informative cancer diagnoses. Singlera has made remarkable progress on applying high-throughput sequencing of methylated circulating tumor DNA (ctDNA) to detecting and diagnosing early-stage cancer.

The funds will help Singlera expand the development and commercialization of its non-invasive genetic tests for early-stage cancer detection and clinical validation studies. Singlera will also use the funds to further expand its research facilities and its TiTanSeq and MONOD platforms into new product lines that address early cancer detection, diagnosis and personalized treatment.